%0 Journal Article
%T Does a fine line exist between regional and metastatic pelvic lymph nodes in rectal cancer¡ªstriking discordance between national guidelines and treatment recommendations by US radiation oncologists
%A Catherine R. Degnin
%A Charles R. Thomas Jr
%A Daniel O. Herzig
%A Jehan Belal Yahya
%A Jerry Jaboin
%A John Holland
%A Kim Lu
%A Matthew Joseph Farrell
%A Simon Brown
%A Timur Mitin
%A Vassiliki Liana Tsikitis
%A Yiyi Chen
%J SCIE-indexed Journal
%D 2018
%X Approximately 40,000 patients are diagnosed with rectal cancer in the United States annually (1). The standard of care for locally advanced Stage II (T3¨CT4, N0, M0) and Stage III (Tany, N+, M0) rectal cancer, based on the results of a randomized German rectal trial (2), is preoperative chemoradiation therapy, followed by total mesorectal excision (TME) and additional adjuvant chemotherapy¡ªwith the goal of achieving greater than 60% of 5-year disease-free survival. In contrast, patients with metastatic disease are treated less aggressively, with the goal of prolonging survival and decreasing disease-related symptoms, but rarely with a curative intent
%U http://jgo.amegroups.com/article/view/20097/html